What makes an SAE a SUSAR?
A Serious Adverse Event (SAE) is any Adverse Event that results in the opinion of the Investigator or Sponsor in: Death or is life-threatening (immediate risk of death) Hospitalization or prolongation of existing hospitalization.
What is SUSAR in pharmacovigilance?
Definition: Any unfavourable occurrence in a trial participant that is judged to have a major impact on their health, was not anticipated and could potentially be due to the intervention under investigation.
What is SUSAR submission?
SUSAR – Suspected Unexpected Serious Adverse Events Reporting.
What is SUSAR line listing?
Once every six months, a line listing of SUSARs must be submitted to the reviewing committee (accredited MREC or CCMO). This line listing provides an overview of all SUSARs for the study medicinal product that have occurred since that last update of the Investigator’s Brochure or the SPC text.
Why do we report SUSAR?
The main purpose of the SUSARs is to protect patient safety but also to inform investigators of new developments, ensure compliance with applicable regulations and study integrity.
WHO reports a SUSAR?
Fatal or life-threatening serious unexpected suspected adverse reactions (SUSARs) reports: The sponsor (or sponsor-investigator) must notify the FDA of any SUSARs to the study drug as soon as possible but no later than 7 calendar days after the initial receipt of the information.
What is SAE form?
Serious Adverse Event Form (SAE)
What is the reporting timeline for expedited reports?
The FDA has long had a rule (21 CFR 312.32) calling for prompt (within 15 days) reporting of any serious unexpected (i.e., not in the investigators’ brochure or labeling) adverse experience “associated with use of a drug” (i.e., if there was a reasonable possibility that the drug may have caused the event).
What is SAE reporting?
Serious Adverse Event (SAE): Any adverse event that: • Results in death. • Is life threatening, or places the participant at immediate risk of death from the. event as it occurred. • Requires or prolongs hospitalization.
Who is responsible for SUSAR reporting to investigators?
The Sponsor
Only U.S. regulations give a clear, 15-day timeline for reporting SUSARs to clinical trial investigators. The EU Clinical Trials Directive states that “The Sponsor shall also inform all investigators” but gives no timeline on reporting to investigators.
When should SAE be reported?
For serious and unexpected, but non-fatal adverse events, file as soon as possible and no later than 15 days after initial receipt of the SAE. All SAEs must be reported to the IRB within 5 business days as “reportable new information.”
What is the difference between SAR and SUSAR?
An SAE that occurs during research with a medicinal product is a SAR if there is a certain degree of probability that the SAE is a harmful and undesired reaction to the investigational medicinal product, regardless of the administered dose. If the SAR is unexpected it is called a SUSAR.
What is an a SAE?
A SAE refers to an event where the individual subject/s was put at risk of harm at the time of the event. It is not an SAE if it has not occurred, yet might occur. A hypothetical situation is not a SAE. 3 – A suspected unexpected serious adverse reaction (SUSAR)
What is a ‘SUSAR’?
If the SAR is unexpected it is called a SUSAR. In this case ‘unexpected’ means that the nature and severity of the SAR do not match with the reference safety information (RSI) as included in the SPC text or Investigator’s Brochure. SUSARs have to be reported to the reviewing MREC from the moment the dossier is submitted.
What is the R&D process for SAE/SAR/SUSAR sponsorships?
R&D and the individuals involved in the SAE/SAR/SUSAR must follow up the event until resolved. R&D will stipulate the timeline and reporting information on their acceptance slip and detail any further requirements needed from the team, in-order to fulfil their sponsor responsibilities.